Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review

<div>Sequential findings of cutaneous lesions on the dorsum of the hand and elbow before the initiation of treatment (a, d), before the addition of rituximab (RTX) (b, e), and after RTX administration (c, f).</div>

Case Reports in Rheumatology

fig2

Figure 2

Figure 2: Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review 

Figure 2 | Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review 